您的位置: 首页 > 2022年1月 第52卷 第1期 > 文字全文
2023年7月 第38卷 第7期11
目录

穿心莲内酯对慢阻肺疾病急性加重期患者的影响

Impact of andrographolide in patients with acute exacerbation of chronic obstructive pulmonary disease

来源期刊: 广州医药 | 6-11 发布时间:2022-04-12 收稿时间:2025/11/13 18:25:29 阅读量:17
作者:
关键词:
穿心莲内酯慢性阻塞性肺疾病急性加重期炎症因子肺功能
andrographolideacute exacerbation of chronic obstructive pulmonary diseaseinflammatory factorspulmonary function
DOI:
10.3969/j.issn.1000-8535.2022.01.002
收稿时间:
2021-06-01 
修订日期:
 
接收日期:
 
引用总数:
5  
目的 本文旨在研究穿心莲内酯对慢性阻塞性肺疾病急性加重期(acute exacerbation of chronic obstructive pulmonary disease,AECOPD)患者血清学中的炎症反应因子及肺部功能改变的影响。方法 从我院已出院的患者中挑选2017年6月—2018年6月期间收治的AECOPD患者共80例,其中给予哌拉西林舒巴坦抗感染和雾化吸入布地奈德及复方异丙托溴铵治疗的患者为对照组,对照组的治疗方法基础上给予喜炎平注射液的患者为观察组,各40例。对2组患者接受治疗前后血清学中的基质金属蛋白酶-9 (matrix metalloproteinase-9, MMP-9)、降钙素原 (procalcitonin, PCT)、白介素-6 (interleukin-6, IL-6) 水平和肺功能指标等方面进行比较。结果 2组治疗前血清学MMP-9、PCT、IL-6和肺功能指标第1秒用力呼气容积(forced expiratory volume in one second, FEV1)、用力肺活量(forced vital capacity, FVC)、一秒率(FEV1/FVC)无差异(P>0.05)。观察组经过治疗后MMP-9为(1995.13±347.281)pg/mL、IL-6为(7.98±3.23)pg/mL,低于对照组的(2159.30±367.477)pg/mL、(10.03±5.45)pg/mL(P<0.05);观察组治疗后的PCT、FEV1、FVC和FEV1/FVC与对照组相比差异无统计学意义 (P>0.05)。结论 穿心莲内酯在AECOPD患者中可以减少血清学中炎症因子,值得在临床中推广。
Objective To investigate the effect of andrographolide on levels of serum inflammatory factors and pulmonary function in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods Eighty patients with AECOPD who were treated in our hospital from June 2017 to June 2018 were selected. Forty patients in the control group were given anti-infection treatment with piperacillin and sulbactam and aerosol inhalation with compound ipratropium bromide and budesonide, while other 40 patients in study group were given andrographolide additionally. The levels of serum matrix metalloproteinase-9 (MMP-9), procalcitonin (PCT), interleukin-6 (IL-6) and the pulmonary function indexes of patients in the two groups were observed and compared before and after treatment. Results There were no statistically significant differences in the serum levels of MMP-9, PCT and IL-6 and the pulmonary function indexes forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and FEV1/FVC of the two groups before treatment (P>0.05). After treatment, in the study group, the MMP-9 and IL-6 levels in serum were (1995.13±347.281)pg/mL and (7.98±3.23)pg/mL respectively, which were significantly lower than that in the control group [(2159.30±367.477) pg/mL and (10.03±5.45) pg/mL (P<0.05)].Compared with the control group, differences in the PCT, FEV1, FVC and FEV1/FVC in the study group were not statistically significant (P>0.05). Conclusion Andrographolide had significant clinical effect on the treatment of AECOPD, which could reduce the levels of serum inflammatory factors and it is worthy of clinical application.
1、 ARIFULLAH M, NAMSA N D, MANDAL M, et al. Evaluation of anti-bacterial and anti-oxidant potential of andrographolide and echiodinin isolated from callus culture of Andrographis paniculata Nees[J]. Asian Pac J Trop Biomed, 2013, 3(8): 604-610. ARIFULLAH M, NAMSA N D, MANDAL M, et al. Evaluation of anti-bacterial and anti-oxidant potential of andrographolide and echiodinin isolated from callus culture of Andrographis paniculata Nees[J]. Asian Pac J Trop Biomed, 2013, 3(8): 604-610.
2、 WHITE A J, GOMPERTZ S, STOCKLEY R A. Chronic obstructive pulmonary disease. 6: The aetiology of exacerbations of chronic obstructive pulmonary disease[J]. Thorax, 2003, 58(1): 73-80. WHITE A J, GOMPERTZ S, STOCKLEY R A. Chronic obstructive pulmonary disease. 6: The aetiology of exacerbations of chronic obstructive pulmonary disease[J]. Thorax, 2003, 58(1): 73-80.
3、 WEDZICHA J A, SEEMUNGAL T A R. COPD exacerbations: defining their cause and prevention[J]. Lancet, 2007, 370(9589): 786-796. WEDZICHA J A, SEEMUNGAL T A R. COPD exacerbations: defining their cause and prevention[J]. Lancet, 2007, 370(9589): 786-796.
4、 SOLER N, TORRES A, EWIG S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation[J]. Am J Respir Crit Care Med, 1998, 157(5): 1498-1505. SOLER N, TORRES A, EWIG S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation[J]. Am J Respir Crit Care Med, 1998, 157(5): 1498-1505.
5、 BAO Z, GUAN S, CHENG C, et al. A novel antiinflammatory role for andrographolide in asthma via inhibition of the nuclear factor-κB pathway[J]. Am J Respir Crit Care Med, 2009, 179(8): 657-665. BAO Z, GUAN S, CHENG C, et al. A novel antiinflammatory role for andrographolide in asthma via inhibition of the nuclear factor-κB pathway[J]. Am J Respir Crit Care Med, 2009, 179(8): 657-665.
6、 CHEN H W, LIN A H, CHU H C, et al. Inhibition of TNF-α-induced inflammation by andrographolide via down-regulation of the PI3K/Akt signaling pathway[J]. J Nat Prod, 2011, 74(11): 2408-2413. CHEN H W, LIN A H, CHU H C, et al. Inhibition of TNF-α-induced inflammation by andrographolide via down-regulation of the PI3K/Akt signaling pathway[J]. J Nat Prod, 2011, 74(11): 2408-2413.
7、 LI F, LI S. Effects of andrographolide on the activation of mitogen activated protein kinases and nuclear factor-κB in mouse peritoneal macrophage-derived foam cells[J]. Chin J Integr Med, 2012, 18(5): 391-394. LI F, LI S. Effects of andrographolide on the activation of mitogen activated protein kinases and nuclear factor-κB in mouse peritoneal macrophage-derived foam cells[J]. Chin J Integr Med, 2012, 18(5): 391-394.
8、 LEE K C, CHANG H H, CHUNG Y H, et al. Andrographolide acts as an anti-inflammatory agent in LPS-stimulated RAW264.7 macrophages by inhibiting STAT3-mediated suppression of the NF-κB pathway[J]. J Ethnopharmacol, 2011, 135(3): 678-684. LEE K C, CHANG H H, CHUNG Y H, et al. Andrographolide acts as an anti-inflammatory agent in LPS-stimulated RAW264.7 macrophages by inhibiting STAT3-mediated suppression of the NF-κB pathway[J]. J Ethnopharmacol, 2011, 135(3): 678-684.
9、 VOGELMEIER C F, CRINER G J, MARTINEZ F J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary[J]. Am J Respir Crit Care Med, 2017, 195(5): 557-582. VOGELMEIER C F, CRINER G J, MARTINEZ F J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary[J]. Am J Respir Crit Care Med, 2017, 195(5): 557-582.
10、 郑劲平, 高怡. 肺功能检查实用指南[M]. 北京: 人民卫生出版社, 2009. 郑劲平, 高怡. 肺功能检查实用指南[M]. 北京: 人民卫生出版社, 2009.
11、 HERESI G A, AYTEKIN M, HAMMEL J P, et al. Plasma interleukin-6 adds prognostic information in pulmonary arterial hypertension[J]. Eur Respir J, 2014, 43(3): 912-914. HERESI G A, AYTEKIN M, HAMMEL J P, et al. Plasma interleukin-6 adds prognostic information in pulmonary arterial hypertension[J]. Eur Respir J, 2014, 43(3): 912-914.
12、 ANSARIN K, RASHIDI F, NAMDAR H, et al. Echocardiographic evaluation of the relationship between inflammatory factors (IL6, TNFα, hs-CRP) and secondary pulmonary hypertension in patients with COPD. A cross sectional study[J]. Pneumologia, 2015, 64(3): 31-35. ANSARIN K, RASHIDI F, NAMDAR H, et al. Echocardiographic evaluation of the relationship between inflammatory factors (IL6, TNFα, hs-CRP) and secondary pulmonary hypertension in patients with COPD. A cross sectional study[J]. Pneumologia, 2015, 64(3): 31-35.
13、 SINGH S, VERMA S K, KUMAR S, et al. Correlation of severity of chronic obstructive pulmonary disease with potential biomarkers[J]. Immunol Lett, 2018(196): 1-10. SINGH S, VERMA S K, KUMAR S, et al. Correlation of severity of chronic obstructive pulmonary disease with potential biomarkers[J]. Immunol Lett, 2018(196): 1-10.
14、 王丽,谭焰,谷伟,等.慢性阻塞性肺病缓解期患者血清中TNF-α、IL-6和IL-8表达的研究[J].临床肺科杂志,2011,16(6):835-836. 王丽,谭焰,谷伟,等.慢性阻塞性肺病缓解期患者血清中TNF-α、IL-6和IL-8表达的研究[J].临床肺科杂志,2011,16(6):835-836.
15、 LEE H. Procalcitonin as a biomarker of infectious diseases[J]. Korean J Intern Med, 2013, 28(3): 285. LEE H. Procalcitonin as a biomarker of infectious diseases[J]. Korean J Intern Med, 2013, 28(3): 285.
16、 LIU H H, ZHANG M W, GUO J B, et al. Procalcitonin and C-reactive protein in early diagnosis of sepsis caused by either Gram-negative or Gram-positive bacteria[J]. Ir J Med Sci, 2017, 186(1): 207-212. LIU H H, ZHANG M W, GUO J B, et al. Procalcitonin and C-reactive protein in early diagnosis of sepsis caused by either Gram-negative or Gram-positive bacteria[J]. Ir J Med Sci, 2017, 186(1): 207-212.
17、 MüLLER B, HARBARTH S, STOLZ D, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia[J]. BMC Infect Dis, 2007, 7(1): 10. MüLLER B, HARBARTH S, STOLZ D, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia[J]. BMC Infect Dis, 2007, 7(1): 10.
18、 SCHUETZ P, CHRIST-CRAIN M, THOMANN R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial[J]. JAMA, 2009, 302(10): 1059-1066. SCHUETZ P, CHRIST-CRAIN M, THOMANN R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial[J]. JAMA, 2009, 302(10): 1059-1066.
19、 RIEDEL S. Procalcitonin and the role of biomarkers in the diagnosis and management of sepsis[J]. Diagn Microbiol Infect Dis, 2012, 73(3): 221-227. RIEDEL S. Procalcitonin and the role of biomarkers in the diagnosis and management of sepsis[J]. Diagn Microbiol Infect Dis, 2012, 73(3): 221-227.
20、 LINDER R, ROMMARK E, POURAZAR J, et al. Serum metalloproteinase-9 is related to COPD severity and symptoms-cross-sectional data from a population based cohort-study[J]. Respir Res, 2015, 16(1): 28. LINDER R, ROMMARK E, POURAZAR J, et al. Serum metalloproteinase-9 is related to COPD severity and symptoms-cross-sectional data from a population based cohort-study[J]. Respir Res, 2015, 16(1): 28.
21、 PAPAKONSTANTINOU E, KARAKIULAKIS G, BATZIOS S, et al. Acute exacerbations of COPD are associated with significant activation of matrix metalloproteinase 9 irrespectively of airway obstruction, emphysema and infection[J]. Respir Res, 2015, 16(1): 78. PAPAKONSTANTINOU E, KARAKIULAKIS G, BATZIOS S, et al. Acute exacerbations of COPD are associated with significant activation of matrix metalloproteinase 9 irrespectively of airway obstruction, emphysema and infection[J]. Respir Res, 2015, 16(1): 78.
22、 WOODE D, SHIOMI T, D'ARMIENTO J. Collagenolytic matrix metalloproteinases in chronic obstructive lung disease and cancer[J]. Cancers, 2015, 7(1): 329-341. WOODE D, SHIOMI T, D'ARMIENTO J. Collagenolytic matrix metalloproteinases in chronic obstructive lung disease and cancer[J]. Cancers, 2015, 7(1): 329-341.
23、 CHAUDHURI R, MCSHARRY C, BRADY J, et al. Low sputum MMP-9/TIMP ratio is associated with airway narrowing in smokers with asthma[J]. Eur Respir J, 2014, 44(4):895-904. CHAUDHURI R, MCSHARRY C, BRADY J, et al. Low sputum MMP-9/TIMP ratio is associated with airway narrowing in smokers with asthma[J]. Eur Respir J, 2014, 44(4):895-904.
24、 SORIANO J B, ABAJOBIR A A, ABATEK H, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015[J]. Lancet Respir Med, 2017, 5(9): 691-706. SORIANO J B, ABAJOBIR A A, ABATEK H, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015[J]. Lancet Respir Med, 2017, 5(9): 691-706.
25、 新型冠状病毒感染的肺炎诊疗方案(第六版试行)[S]. 国家卫生健康委办公厅,2020. 新型冠状病毒感染的肺炎诊疗方案(第六版试行)[S]. 国家卫生健康委办公厅,2020.
26、 WANG C, XU J, YANG L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health[CPH] study): a national cross-sectional study[J]. Lancet, 2018, 391(10131): 1706-1717. WANG C, XU J, YANG L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health[CPH] study): a national cross-sectional study[J]. Lancet, 2018, 391(10131): 1706-1717.
1、汪嘉琦.吸烟对肺损伤的干预研究及对人群心血管事件影响的队列研究[D].东南大学,2022.DOI:10.27014/d.cnki.gdnau.2022.000864. 汪嘉琦.吸烟对肺损伤的干预研究及对人群心血管事件影响的队列研究[D].东南大学,2022.DOI:10.27014/d.cnki.gdnau.2022.000864.
2、李景梅.基于蛋白酶/抗蛋白酶失衡探讨益肺灸及其联合调补肺肾三法对慢性阻塞性肺疾病稳定期大鼠肺泡结构的影响[D].河南中医药大学,2022.DOI:10.27119/d.cnki.ghezc.2022.000138. 李景梅.基于蛋白酶/抗蛋白酶失衡探讨益肺灸及其联合调补肺肾三法对慢性阻塞性肺疾病稳定期大鼠肺泡结构的影响[D].河南中医药大学,2022.DOI:10.27119/d.cnki.ghezc.2022.000138.
3、李基垚.A100纳米晶肺部给药对COPD小鼠的药效学研究[D].河南大学,2024.DOI:10.27114/d.cnki.ghnau.2024.000010. 李基垚.A100纳米晶肺部给药对COPD小鼠的药效学研究[D].河南大学,2024.DOI:10.27114/d.cnki.ghnau.2024.000010.
4、李景梅,沈婷婷,李亚,等.慢性阻塞性肺疾病蛋白酶/抗蛋白酶失衡机制及中医药干预探讨[J].中医药学报,2023,51(05):11-16.DOI:10.19664/j.cnki.1002-2392.230095. 李景梅,沈婷婷,李亚,等.慢性阻塞性肺疾病蛋白酶/抗蛋白酶失衡机制及中医药干预探讨[J].中医药学报,2023,51(05):11-16.DOI:10.19664/j.cnki.1002-2392.230095.
5、李海萍,雷佩珊.基于“随其所得而攻之”理论探讨慢性阻塞性肺疾病辨治思路[J].中医临床研究,2025,17(11):27-33. 李海萍,雷佩珊.基于“随其所得而攻之”理论探讨慢性阻塞性肺疾病辨治思路[J].中医临床研究,2025,17(11):27-33.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录